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Abstract: Progress in continuous flow chemistry over the past two decades has facilitated significant
developments in the flow synthesis of a wide variety of Active Pharmaceutical Ingredients (APIs),
the foundation of Continuous Pharmaceutical Manufacturing (CPM), which has gained interest for
its potential to reduce material usage, energy and costs and the ability to access novel processing
windows that would be otherwise hazardous if operated via traditional batch techniques. Design
space investigation of manufacturing processes is a useful task in elucidating attainable regions of
process performance and product quality attributes that can allow insight into process design and
optimization prior to costly experimental campaigns and pilot plant studies. This study discusses recent
demonstrations from the literature on design space investigation and visualization for continuous API
production and highlights attainable regions of recoveries, material efficiencies, flowsheet complexity
and cost components for upstream (reaction + separation) via modeling, simulation and nonlinear
optimization, providing insight into optimal CPM operation.
Keywords: Continuous Pharmaceutical Manufacturing (CPM); Active Pharmaceutical Ingredients
(APIs); design space investigation; technoeconomic analysis
1. Introduction
Increasing pharmaceutical Research and Development (R&D) expenditures necessitate the need
for leaner manufacturing with reduced costs. There has been significant research focus on continuous
Active Pharmaceutical Ingredient (API) production due to pressure on the pharmaceutical industry to
reduce drug development times, minimize product quality variation and process deviations, decrease
overall costs and minimize environmental impact with lower capital and operating expenditures that
are inherent of the smaller equipment and material usage reductions with continuous operations [1,2].
The chemistry, chemical engineering and process systems engineering communities have approached
both unit operation and plantwide Continuous Pharmaceutical Manufacturing (CPM) from both
experimental (laboratory and pilot plants) and theoretical (mathematical modeling, simulation and
optimization) perspectives to elucidate promising designs for continuous API production [3,4].
Design space investigation for different process options is a useful task in elucidating critical
process parameters as well as understanding the attainable region of product quality attributes and
technoeconomic performances. Our group has conducted many studies in technoeconomic modeling,
simulation and optimization of CPM for a variety of APIs, including both upstream plants (flow
synthesis + purification/separation) and isolated separation trains (e.g., crystallization cascades).
An understanding of the attainable performances within design spaces for different APIs that have been
realized as amenable to CPM (from studies in the literature) can be useful in elucidating technoeconomic
viability vs. existing processes. Therein lies the novelty of this study.
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This paper is structured as follows. First, we discuss the need for design space investigation
and visualization for CPM design, followed by a review of some pertinent literature, including API
flow synthesis, purification/separation and downstream unit operations. We then consider upstream
CPM case studies conducted by our group, which have utilized conceptual modeling, simulation
and optimization—Nonlinear Programming (NLP) and Mixed Integer Nonlinear Programming
(MINLP)—for comparative technoeconomic evaluation of CPM designs. A critical discussion of these
cases is then provided with an outlook to the future of this vibrant research field.
2. Related Literature
This section is structured as follows. First, we discuss different stages of pharmaceutical manufacturing
and literature studies (experimental, industrial and theoretical) on continuous applications: Section 2.1
discusses API continuous flow synthesis, Section 2.2 considers continuous flow synthesis and
purification + separation process design and Section 2.3 focuses on examples of downstream processing
and Drug Product (DP) formulation. Subsequently, Section 2.4 discusses the industrial adoption of
CPM and the need for an understanding of regions of attainable performances of APIs that have been
demonstrated as amenable to CPM. Section 2.5 then discusses design space investigation for CPM, how
modeling, simulation and optimization methodologies can be used to rapidly screen process designs
and elucidate attainable regions, and describes literature examples of design space investigation for
different stages of CPM. Section 2.6 then summarizes the relevant literature discussed and provides
the motivation, aims and objectives of this paper.
2.1. Continuous Flow Synthesis of Active Pharmaceutical Ingredients
The development of continuous flow technology and synthetic strategies by chemists and
engineers has been the focus of significant research attention over the past two decades due to the wide
variety of chemical processes whose performance can be improved or intensified by switching from
batch to continuous flow operation. While continuous manufacturing is the norm in many process
industries (e.g., oil and gas production), continuous operation is less frequented in pharmaceutical
manufacturing due to significant investments in batch infrastructures and various other advantages [5].
Operating continuously allows for smaller equipment dimensions, wherein mixing and heat transfer
are significantly enhanced, improving yields, selectivities, productivities and allowing access to novel
operating windows that would be otherwise hazardous in batch mode [6]. Several reviews in the past
few years have documented the rapid development of continuous flow synthesis technology for fine
chemical and pharmaceutical products [7–12].
2.2. Continuous Pharmaceutical Separation Process Design
The development of continuous separation processes as part of end-to-end CPM plants is essential
for reaction effluent purification and crystallization prior to downstream unit operations. While
some demonstrations of fully continuous plants (including synthesis, purification and drug product
formulation) have been highlighted in the past decade [13–15], there is generally a lack of continuous
separation process design in the literature in comparison to research efforts in flow synthesis [16],
especially as part of integrated plants. That said, there have been investigations into the design,
operation and optimization of isolated continuous pharmaceutical separation processes.
A variety of different separation processes are implemented in pharmaceutical manufacturing
processes, including (but not limited to) Liquid–Liquid Extraction (LLE), membrane purification/separation,
distillation, crystallization and chromatographic separations. Modeling and optimization have been
implemented in the design of continuous chromatographic methods [17] and membrane separations [18]
for pharmaceutical manufacturing. Here, we focus on the design of continuous LLE and crystallization
processes, both of which are very commonly implemented purification and separation processes
essential to pharmaceutical manufacturing.
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2.2.1. Liquid-Liquid Extraction
The aim of LLE is to purify a multicomponent mixture by addition of a solvent which induces
the splitting of the mixture into multiple phases, between which solutes partition; the objective is
to partition undesired solute component (e.g., impurities) into one phase while the desired solute
(e.g., product API) preferentially partitions into the other. Purification via LLE is typically implemented
in pharmaceutical processes prior to crystallization to ensure as few undesirable impurities as possible
are incorporated into crystalline products. The design of continuous LLE processes is an important
aspect of end-to-end CPM plant development.
The majority of LLE process demonstrations are still done in batch, even with a continuous
flow synthesis demonstration. That said, there have been a few experimental as well as theoretical
studies on the design of continuous LLE processes. Drageset and Bjørsvik (2016) performed an
in-line continuous LLE for purification of a reactor product mixture prior to further downstream
processing, allowing for significant material reduction compared to the batch purification process [19].
Monbaliu et al. (2016) also implemented a continuous LLE process as part of an end-to-end CPM
process for lidocaine hydrochloride (a local anesthetic) from synthesis to aqueous formulation [20].
Implementation of combined experimental and modeling approaches towards integrated LLE design
described in the literature for pharmaceutical purifications and separations demonstrate the utility of
theoretical methods in establishing optimal design and operating parameters [19–21].
2.2.2. Crystallization
A significant portion of pharmaceutical products are sold as solids (tablets, dispersions, gels
or topical treatments), and thus crystallization is an essential unit operation in Drug Product (DP)
manufacturing. The aim of crystallization is to form a solid product of the desired compound with
minimal impurity + solvent incorporation into the crystal structure while also attaining the desired
polymorph, suitable mean crystal size and size distribution properties, all of which affect subsequent
downstream process unit operations and the bioavailability of the drug in the patient.
Continuous crystallization has received attention for its potential to increase flexibility, efficiency
and quality [22]. Continuous crystallization operates under steady-state conditions, allowing higher
reproducibility and better control of important crystal properties such as the purity and the size
distribution; however, as continuous processes do not discharge at equilibrium, they tend to achieve
lower yields than batch crystallizations [23]. Continuous crystallizer designs applicable for the
pharmaceutical industry are categorized as Plug Flow Crystallizers (PFCs), Continuous Oscillatory
Baffled Crystallizers (COBCs) or Mixed Suspension–Mixed Product Removal (MSMPR) crystallizers.
PFCs are suited to systems with fast crystal growth and short residence times and can attain narrow
crystal size distributions [24], but fouling and clogging in narrow tube diameters is an important
technical issue [25]. COBCs are another emerging technology, which enhance heat and mass transfer, but
have issues handling streams with high solid loadings [26]. Various experimental and modeling studies
have been conducted for the estimation of crystallization kinetics, proof-of-concept demonstrations
and design and optimization processes [27–32].
2.3. Continuous Downstream Processing + Drug Product Formulation
Pharmaceutical manufacturing can be classified into distinct stages in series: synthesis, the single-
or multistep reaction to form the target API molecule from reagents; purification and separation,
the removal of API/impurities from the reaction mixture to sufficient purity that is often followed
by crystallization due to most drugs being administered as solids; and formulation, where the Drug
Product (DP) is made, making the API into a form that is consumable and effective.
Downstream processing for DP formulation is an essential set of stages in a pharmaceutical plant
in order to yield the final product in the form by which it will be administered. As such, stringent
product quality assurance in these stages is paramount. Continuous manufacturing in these stages is
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required for successful end-to-end CPM implementation (i.e., all stages of the plant are continuous
without intermediate batch processing required).
Various unit operations exist for the formulation of different types of DPs, depending on the
form in which it is to be administered to the patient. Different studies consider varying flowsheet
complexities and combinations of unit operations, a few pertinent literature examples of which are
briefly described here. Su et al. (2019) implemented model predictive control to attain specific product
quality attributes that were met for a rotary tablet press (composed of filling, metering, compression
and tablet ejection) as part of a downstream pilot plant [33]. Martinetz et al. (2017) also considered a
similar continuous rotary tablet press, which was designed to be robust with respect to varying feed
flow rates for different product formulations [34]. Metta et al. (2019) performed design and dynamic
simulation of a continuous tableting line (composed of feeders, blenders, wet granulation, fluidized
bed drying, milling + tablet press). The authors elucidated the critical process parameters affecting
product quality that needed to be ensured in order to facilitate robust process design [35].
Hsu et al. (2010) formulated a dynamic model for continuous roller compaction using a model
based approach which was subsequently used for control due to the process being very sensitive
to inlet bulk density [36,37]. Bano et al. (2019) also considered the continuous roller compaction of
microcrystalline cellulose, combining first-principles methods with plant data to establish the alteration
of the design space subject to process disturbances and uncertainty [38]. Tian et al. (2019) considered a
continuous direct compression line (feeders, blenders + press) which was modelled and simulated
following a sensitivity analysis for the elucidation of critical process parameters [39].
2.4. Industrial Adoption of Continuous Pharmaceutical Manufacturing
While manufacturing sectors such as the oil and gas industry traditionally operate in continuous
mode, pharmaceutical production is traditionally batchwise, only implementing continuous mode for
select cases in the past decade. Continuous manufacturing was highlighted as a key green chemistry
principle by various industrial and regulatory bodies [1,40], with various efforts towards generalizing
methodologies towards facilitation of the transition of batch to continuous processes [2,3]. That said,
the selection of which processes can be conducted continuously is still predominantly done on a
case-by-case basis. Here, we list some examples of adoption of continuous manufacturing for different
pharmaceutical processes at different scales.
The first fully end-to-end CPM plant was demonstrated by Mascia et al. (2013), where aliskiren
hemifumarate was synthesized, purified, crystallized and subsequently formulated into the desired
DP whilst mitigating solids handling issues and removing the need for intermediate solvent swaps
between unit operations [41]. Adamo et al. (2016) also demonstrated a compact, end-to-end
production of multiple DPs with different APIs [13]. Monbaliu et al. (2016) developed an automated
system for the end-to-end CPM of lidocaine hydrochloride [20]; Cole et al. (2019) described the
end-to-end CPM of merestinib (a new biliary tract cancer drug) from synthesis to crystallization [14,15].
The above-mentioned demonstrations were implemented on pilot or production plant level.
The implementation of CPM at production level has begun to appear more prevalently in
recent years for plant subsystem and plantwide designs [42–44]. Vertex committed to continuous
Orkambi (containing lumacaftor and ivacaftor for cystic fibrosis treatment) tableting [45]. GSK began
continuous production of amoxicillin at a fully continuous plant in Singapore [46] and also began
a continuous line for daprodusat (a new anemia mediation) [47,48]. In 2016, Janssen received FDA
approval for the continuous tablet production for Prezista, whose API, darunavir, is used as part of
HIV/AIDS combinative treatments [49]. Eli Lilly recently committed a significant capital investment to
a continuous production plant in Ireland [50].
The relatively few examples of industrial adoption of CPM highlights a need for understanding
the attainable process performances of candidate designs to ensure CPM success; this is where design
space investigation via modeling, simulation and optimization can be useful tools.
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2.5. Design Space Investigation
The literature contains many examples of design space investigation studies for both batch and
CPM processes on the unit operation, subsystem or plant level. Here, we describe some pertinent
examples of such studies in flow synthesis, separation and downstream processing.
2.5.1. Continuous Flow Synthesis
The demonstration of continuous flow chemistry of an API (i.e., in which the synthesis is performed
in flow as opposed to in batch) is the foundation of any CPM process; however, subsequent purification
+ separation (upstream) and DP formulation (downstream) unit operations are often challenging
and expensive processes that must be considered in the comparative evaluation of different designs.
Establishing feasible operating regions to meet desired product quality and process performance
targets is an important part of design in various CPM studies.
Process chemists often spend extensive periods of time attempting to find optimal reaction
conditions (temperature, residence time, reagent and/or base concentration, catalyst loading etc.) in
order to maximize product yields, selectivities and purities. Whilst a mechanistic understanding of
chemical reactions is useful (via development of deterministic models that can be reparameterized for
use in other similar reaction systems), their development can be time-consuming and a data-driven
approach may be more convenient for the specific application. However, retrieving sufficient data to
have a meaningful data-driven model can be laborious and time-consuming in itself. For this reason,
the development of automated continuous flow systems for reaction is a hot topic of research.
Bédard et al. (2018) developed a continuous synthesis system composed of reagent/feedstocks
and pumps and interchangeable reactor and separator modules with online analytics and a software
interface for process control and reaction monitoring (Figure 1). The authors demonstrated a variety
of pharmaceutical reactions in flow, elucidating optimal regions of operation regarding operating
temperature, residence time, reagent ratios, catalyst and base loading [51]. The modularity and
automated nature of the system allowed for optimal reaction conditions being elucidated for C–C
and C–N cross-couplings, olefinations, reductive aminations nucleophilic aromatic substitution,
photoredox catalysis and multistep sequences thereof, all of which are highly relevant to the flow
chemistry community, particularly for the continuous synthesis of APIs.
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vs. base equivalents, residence time and reagent molar ratios. Reproduced with permission from
Bédard et al., Science; published by American Association for the Advancement of Science, 2018 [51].
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Armstrong et al. (2019) performed design space investigation to understand the effect of the
critical operating parameters (reagent molar ratios and reaction temperature) on the flow synthesis of
an intermediate to dolutegravir, a HIV integrase inhibitor used in combinative HIV/AIDS treatment
(Figure 2) [52]. The authors also compared the performance and accuracy obtained by design space
investigation using a Computational Fluid Dynamics (CFD) approach vs. experiments, with the CFD
results being comparably accurate but faster and without experimental labor.
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Reizma and J nsen (2015) considered the effect of reaction c rrier solvent for optimization
of a synthesis performed in icroliter slugs, comparing the proces yi ld as a function of reagent
molar ratios and residence time in each considered solvent [53]. The authors screened discrete
(reactor materials, catalyst, base, carrier solvent) and continuous (reaction temperature, residence time)
variables simult neously; their automated system was used to maximize reaction yield. The study is
in a similar vein t Bédard et al. (s e Figure 1), but without th automated experimental setup, which
is not a commercially available rig.
Boros et al. (2019) considered the flow synthesis of vortioxetine (an antidepressant API) from an
intermediate, comparing the effects of temperature and resid nce time on process yield [54]. Their
design space investigation vs. different batch configurations showed improvements with respect to
product yield and purity, illustrating the benefit of design space investigation in order to maximize the
benefits of CPM compared to existing batch processes (Figure 3).
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Wyvratt et al. (2019) characterized the design space of a Knoevenagel condensation (a nucleophilic
addition of a carbanion to a carbonyl compound followed by dehydration, which is a key reaction
stage in the production of many APIs). The authors elucidated the design space by varying residence
time and catalyst loading whilst minimizing the number of experiments and material consumption
required to adequately map the design space (Figure 4). The number of experiments, and hence
material requirements, needed for data-driven reaction modeling is one of the main drawbacks of the
approach; hence, the study provides a valuable methodology for materially-efficient design space
elucidation for flow synthesis [55].
Pharmaceutics 2020, 12, x FOR PEER REVIEW 7 of 24 
 
Wyvratt et al. (2019) characterized the design space of a Knoevenagel condensation (a 
nucleophilic addition of a carbanion to a carbonyl compound followed by dehydration, which is a 
key reaction stage in the production of many APIs). The authors elucidated the design space by 
varying residence time and catalyst loading whilst minimizing the number of experiments a  
material consumption required to a equately map the desig  space (Figure 4). The number of 
experiments, and hence material requirements, needed for data-driven reaction modeling is one of 
the main drawbacks of the approach; hence, the study provides a valuable methodology for 
materially-efficient design space elucidation for flow synthesis [55]. 
 
Figure 4. Flow synthesis design spaces of a Knoevenagel condensation in flow as (A) 3D projection 
with experimental data points, (B) 2D projection. Reproduced with permission from Wyvratt et al., 
Reaction Chemistry & Engineering; published by Royal Society of Chemistry, 2019 [55]. 
Comparative evaluation of batch vs. continuous syntheses are also useful in quantifying 
technoeconomic benefits of different production paradigms and flowsheet configurations [55]. Life 
Cycle Assessment (LCA) has been performed for different flow chemistry and plant design studies 
in the literature for pharmaceuticals and the production of other chemicals. Ott et al. (2016) performed 
LCA for different flowsheet configurations of batch vs. flow microreactor networks for rufinamide 
synthesis, considering various metrics related to plant material efficiencies and environmental 
impacts (including potentials for global warming, human toxicity, natural land transformation, ozone 
depletion, photochemical oxidation and terrestrial acidification and ecotoxicity) of different 
production options (Figure 5) [56]. The authors found that each of the considered batch/continuous 
processes presented inherent trade-offs between different LCA criteria and process chemistry 
options. This study (amongst others) demonstrates typical trade-offs and complexity in process 
synthesis and design selection, which can be aided by detailed design space investigations. 
 
Figure 5. Life Cycle Assessment (LCA) of batch vs. continuous synthesis for rufinamide. Reproduced 
with permission from Ott et al., Green Chemistry; published by Royal Society of Chemistry, 2016 [56]. 
Figure 4. Flow synthesis design spaces of a Knoevenagel condensation in flow as (A) 3D projection
with experimental data points, (B) 2D projection. Reproduced with permission from Wyvratt et al.,
Reaction Chemistry & Engineering; published by Royal Society of Chemistry, 2019 [55].
Comparative evaluation of batch vs. continuous syntheses are also useful in quantifying
technoeconomic benefits of different production paradigms and flowsheet configurations [55]. Life
Cycle Assessment (LCA) as been performed for different flow chemistry and plant design studies in
the literature for pharmaceuticals and the production of other chemi als. Ott et al. (2016) performed
LCA for different flowsheet configurations of batch vs. flow microreactor networks for rufinamide
synthesis, considering various metrics related to plant material efficiencies and environmental impacts
(including potentials for global warming, human toxicity, natural land transformation, ozone depletion,
photochemical oxidation and terrestrial acidification and ecotoxicity) of different production options
(Figure 5) [56]. e a thors f und that each of the considered batch/co tinuous processes presented
inherent trade-offs between different LCA crit ria and process chemistry options. This study (amongst
others) demonstrates typical trade-offs and complexity in process synthesis and design selection, which
can be aided by detailed design space investigations.
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2.5.2. Continuous Separation Process Design
In crystallization processes, critical product quality attributes (mean product size and size
distribution width) that affect downstream processing and drug bioavailability are very sensitive
to process design and operating parameters. Ridder et al. (2014) performed experiments and
modelled the antisolvent crystallization of flufenamic acid in a multisegment, multiaddition plug-flow
crystallizer, where the antisolvent feed rate to different tubular crystallizer segments was varied in
order to either maximize the mean crystal size or minimize the product size distribution coefficient of
variation (Figure 6). The authors presented trade-offs between the two product quality attributes [57].
The study demonstrated the benefits of rigorous modeling and optimization for process design whilst
circumventing expensive experiments to attain specific quality attributes.
Pharmaceutics 2020, 12, x FOR PEER REVIEW 8 of 24 
 
2.5.2. Continuous Separation Process Design 
In crystallization processes, critical product quality attributes (mean product size and size 
distribution width) that affect downstream processing and drug bioavailability are very sensitive to 
process design and operating parameters. Ridder et al. (2014) performed experiments and modelled 
the antisolvent crystallization of flufenamic acid in a multisegment, multiaddition plug-flow 
crystallizer, where the antisolvent feed rate to different tubular crystallizer segments was varied in 
order to either maximize the mean crystal size or minimize the product size distribution coefficient 
of variation (Figure 6). The authors presented trade-offs between the two product quality attributes 
[57]. The study demonstrated the benefits of rigorous modeling and optimization for process design 
whilst circumventing expensive experiments to attain specific quality attributes. 
 
Figure 6. Design space of crystal quality (average size + size distribution coefficient of variation) vs. 
antisolvent addition at different inlets. Reproduced with permission from Ridder et al., Industrial & 
Engineering Chemistry Research; published by American Chemical Society, 2014 [57]. 
In the past decade, process integration and intensification have been recent topics of interest 
within the process chemistry and systems engineering communities for their ability to attain 
otherwise difficult windows of product quality whilst also minimizing equipment dimensions and 
material consumption. Wang and Lakerveld (2017) combined a membrane separation with a MSMPR 
crystallization cascade with mother liquor recycle to maximize particle size by varying crystallizer 
operating temperatures subject to impurity limits, temperature constraints, yield specification, set 
cascade residence time and solvent removal rate [18]. Their results showed that incorporating 
membrane separations into a traditional MSMPR cascade significantly widens the region of attainable 
Figure 6. Design space of crystal qualit ( i e size distribution coefficient of v r ation) vs.
antisolvent ad it on at different inlets. ith permi sion from Ri der et al., Industrial &
Engineering Chemistry Research; publishe i he ical Society, 2014 [57].
In the past decade, process integration a d inte sification have been recent topics of interest within
the process chemistry and sy ems engineering commun ties f r their ability to attain otherwise difficult
windows of produc quality whilst also minimizing equipment di ensions and material consumption.
Wang and Lakerveld (2017) combined a membrane separation with a MSMPR crystall zation cascade
with mother liquor recycle to aximize parti le size by varying crystalli r operati temperatures
subject to impurity limits, temperature constraints, yield specification, set cascade residence time
and solvent removal rate [18]. Their results showed that incorporating membrane separations into a
traditional MSMPR cascade significantly widens the region of attainable product particle sizes whilst
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shortening the total residence time (Figure 7). The regions of attainable product quality were shown to
be significantly larger when implementing longer crystallization cascades with membranes vs. those
without membranes.
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Köllges and Vetter (2019) designed a single MSMPR crystallizer coupled with milling to attain
the stable β-polymorph of l-glutamic acid from aqueous solution, mapping the attainable process
productivities vs. polymorphic regions (Figure 8) [58]. The authors showed that only via addition of a
milling process to the crystallization process allowed for attainment of the β-polymorph, whereas the
crystallizer alone could only produce the metastable α-polymorph. The design space study elucidated
the fact that the fines generation from milling increased the available crystallization surface area,
which enhanced the yield and widened the attainable region of product quality attributes vs. the
crystallization process alone.
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2.5.3. Downstream Processing
Various efforts towards design space investigation and characterization of downstream
pharmaceutical unit operations exist in the literature. Many of these studies make use of statistical
techniques such as Partial Least Squares (PLS) and Principal Component Analysis (PCA) methods
to understand the underlying causalities and correlations between various plant input and output
variables and process parameters, especially when there are significant historical data available
and insufficient time to develop, parameterize and validate more detailed mechanistic models [59].
Bano et al. (2018) elucidated the design spaces for three different pharmaceutical process case studies of
different size (including a blending and tableting subprocess) and complexity using PLS and applying
a Radial Basis Function (RBF) to define the process’ feasible region (Figure 9) [60].
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Wang et al. (2017) considered the design space of a milling + blending + tableting process with
many dimensions (problem variabl s), incl di g str am flowrates, target densities, unit residence
times, holdups, product par icle size distributio proper es and final table p operties such as weight,
hardness and API concentration [61]. P rforming a sensitivity analysis (via M rris Scr ening) on the
effects of inputs vs. outputs aided the elucidation of the feasible region of operation (Figure 10).
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2.6. This Study
It has been illustrated in the above subsections discussing the literature and the state of continuous
manufacturing in the pharmaceutical industry that design space investigation via modeling, simulation
and optimization can be of great utility for CPM development. In this work, we focus on the upstream
CPM of several APIs for which technoeconomic simulation and optimization studies have been
performed in the literature for comparative evaluation of typical attainable process performances.
Observation of trends common between different APIs, despite their widely varying processes and
chemistries, provides a deeper understanding of the attainable process performances for APIs which
are amenable to CPM and can be done so successfully.
3. Plantwide Design Space Investigation
In this study, we concentrate on upstream plantwide CPM studies we have previously done,
encompassing both reaction (flow synthesis) and separation (continuous LLE or crystallization)
phenomena and unit operations as well as detailed Capital (CapEx) and Operating (OpEx) Expenditure
cost components.
3.1. Upstream Plantwide Design Case Studies
The following APIs are considered for analysis in this study: ibuprofen (the popular
analgesic), artemisinin (a potent antimalarial), diphenhydramine (a branded antihistamine), warfarin
(an anticoagulant), atropine (treatment of nerve agent effects) and nevirapine (used in HIV treatments).
3.1.1. Ibuprofen
The continuous flow synthesis of ibuprofen was demonstrated by Bogdan and coworkers
(2009), consisting of three consecutive reactions in flow [62], followed by a conceptual continuous
LLE process [63]—the CPM flowsheet for this process is shown in Figure 11. Isobutylbenzene
(IBB), propanoic acid and neat triflic acid (TfOH, catalyst) enter reactor R-101 where IBB undergoes
Friedel–Crafts acylations to form 1-(4-isobutylphenyl)propan-1-one (1-4-IBPP). After cooling the
effluent of R-101 to 0 ◦C, it is mixed with a stream of diacetoxyiodobenzene (PhI(OAc)2) and trimethyl
orthoformate (TMOF) in methanol (MeOH, at 0 ◦C) prior to entering R-102, where IBPP undergoes
1,2-aryl migration to form 2-(4-isobutylphenyl)propanoate (2-4-IBPP) by catalysis from TfOH. Potassium
hydroxide (KOH) in MeOH + H2O is added to the effluent of R-102; the resulting mixture enters R-103,
where 2-4-IBPP is saponified to form the potassium salt of ibuprofen. The continuous LLE of ibuprofen
from the mixture compares toluene (PhMe) and n-hexane (nHex) as LLE solvents.
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Figure 11. Continuous Pharmaceutical Manufacturing (CPM) flowsheet for ibuprofen: flow synthesis [62]
+ continuous Liquid–Liquid Extraction LLE [63]. Reproduced with permission from Jolliffe and
Gerogiorgis, Computers and Chemical Engineering; published by Elsevier, 2016.
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3.1.2. Artemisinin
The continuous flow synthesis of artemisinin considered is that demonstrated by Kopetzki et al.
(2013), where dihydroartemesinic acid (DHAA) is photoxidized to an intermediate (Int.) by the
photocatalyst dicyanoanthracene (DCA) in R-201 [64]. Various reactions then occur in R-202—the
desired pathway is where the intermediate from R-201 is acid catalyzed (by trifluoroacetic acid, TFA) to
produce another intermediate via terminal protonation, followed by a Hock arrangement into another
intermediate, which can then react with triplet oxygen (3O2) to form artemisinin. The effluent of R-202
is neutralized, followed by purification and antisolvent addition followed by cooling to crystallize
artemisinin [63]. Ethanol (EtOH) and ethyl acetate (EtOAc) are compared as candidate crystallization
antisolvents. The conceptual flowsheet for artemisinin CPM is shown in Figure 12.
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Figure 12. CPM flowsheet for artemisinin: flow synthesis [64] + continuous LLE [63]. Reproduced
with permission from Jolliffe and Gerogiorgis, Computers and Chemical Engineering; published by
Elsevier, 2016.
3.1.3. Diphenhydramine
The continuous flow synthesis of diphenhydramine was demonstrated by Snead and Jamison
(2013), wherein chl rodiphenylm than (CDPM) reacts with dimethylaminoethanol (DMAE) in
N-methlypyrrolid ne (NMP) carrier solvent at 180 ◦C (R-301) [65]. Subseque tly, co ti uous LLE is
performed, comparing cyclohexane (CyHex), methylcyclohexane (MeCyHex) and n-heptane (nHep)
as candidate LLE solvents, performing the LLE at 20 ◦C [66]. The conceptual CPM flowsheet for
diphenhydramine is shown in Figure 13.
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Figure 13. CPM flowsheet for diphenhydramine: flow synthesis [65] + continuous LLE [66]. Reproduced
with permission from Diab and Gerogiorgis, Organic Process Research & Development; published by
American Chemical Society, 2017.
3.1.4. Warfarin
The continuous synthesis of (S)-warfarin was demonstrated by Porta et al. (2015), featuring the
nucleophilic addition of 4-hydroxy-coumarin to benzalacetone in the presence of TFA and a chiral
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amine catalyst in 1,4-dioxane [67]. Upon addition of the candidate LLE solvent, the process forms an
organic (product) phase containing recovered API and an aqueous (waste) phase. Several candidate
separation solvents are compared for continuous LLE: ethyl acetate (EtOAc), isopropyl acetate (iPrOAc)
and isobutyl acetate (iBuOAc). The CPM flowsheet for warfarin is shown in Figure 14 [68].
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Figure 14. CPM flowsheet for warfarin: flow synthesis [67] + continuous LLE [68]. Reproduced
with permission from Diab and Gerogiorgis, Computer Aided Chemical Engineering; published by
Elsevier, 2018.
3.1.5. Atropine
The continuous flow synthesis of atropine was demonstrate by Bédar et al. (2016), featuring
two flow reactions: the esterification f tropine (in dimethylfo mamide, DMF) and neat phenylacetyl
chloride at 100 ◦C (in R-501) to form tropine ester HCl, the free form of which is formed by the addition
of sodium hydroxide (NaOH (aq.)). In R-502, the aldol addition of formaldehyde (CH2O) to the tropine
ester at 100 ◦C under basic conditions forms the API, accompanied by an undesired elimination of
API to apoatropine via condensation [69]. A subsequent continuous LLE in a cascade of vessels is
performed with either diethyl ether (Et2O), n-butyl acetate (BuOAc) or toluene (PhMe) for comparative
evaluation purposes [70]. The CPM flowsheet for atropine is show in Figure 15.
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Figure 15. CPM flowsheet for atropine: flow synthesis [69] + continuous LLE [70]. Reproduced with
permission from Diab and Gerogiorgis, AIChE Journal; published by John Wiley and Sons, 2019.
3.1.6. Nevirapine
The continuous flow synthesis of nevirapine was demonstrated by Verghese et al. (2017). First,
2-chloro-3-amino-4-picoline (CAPIC) and sodium hydride (NaH) form CAPIC-Na salt in diglyme at
95 ◦C in R-601; the effluent enters R-602 with neat 2-(cyclopropylamino)nicotinate (MeCAN) at 65 ◦C
to form N-(2-chloro-4-methylpyridin-3-yl)-2-(cyclopropylamino)nicotinamide (CYCLOR). In the final
Pharmaceutics 2020, 12, 235 14 of 24
reactor (R-603), CYCLOR flows over a packed bed of NaH to form nevirapine [71]. A subsequent
purification and crystallization via pH change is performed to obtain purified API crystals. Different
assumptions of solvent recovery, SR = {0%, 40%, 80%} (reflecting worst case, intermediate and
laboratory-scale demonstrated recovery demonstrations, respectively), are considered. The CPM
flowsheet for nevirapine is shown in Figure 16 [72].
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design option details for the different processes. 
Table 1. Summary of separation design options for each API case study. 
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No. Stages Refs. 
Methodology 
Synth. Sep. Synth. Sep. 
Ibuprofen Analgesic LLE 
PhMe 3 1 [62] [63] Simulation 
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EtOH 2 1 [64] [63] Simulation 
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Figure 16. CPM flowsheet for nevirapine: flow synthesis [71] + continuous crystallization [72].
Reproduced with permission from Diab et al., Organic Process Research & Development; published by
American Chemical Society, 2019.
The extent of modeling, simulation and optimization for the different API case studies considered
vary: ibuprofen, artemisinin and diphenhydramine implement process simulation for design
space investigation; warfarin and nevirapine studies implement Nonlinear Programming (NLP)
for plantwide optimization for total cost minimization; atropine CPM implements Mixed Integer
Nonlinear Programming (MINLP) for process synthesis o optimali y, i.e., plant total cost minimization.
Details of steady-stat modeli g, simulation and optimization implemented for each case study can be
found in our previous research contributions listed above. Table 1 summarizes design option details
for the different processes.
Table 1. Summary of separation design options for each API case study.
API Application Separation Option
No. Stages Refs.
Methodology
Synth. Sep. Synth. Sep.
Ibuprofen Analgesic LLE
PhMe 3 1 [62] [63] Simulation
nHex 3 1 [62] [63] Simulation
Artemisinin Antimalarial Crystallization
EtOH 2 1 [64] [63] Simulation
EtOAc 2 1 [64] [63] Simulation
Diphenhydramine Antihistamine LLE
CyHex 1 1 [65] [66] Simulation
MeCyHex 1 1 [65] [66] Simulation
nHep 1 1 [65] [66] Simulation
Warfarin Anticoagulant LLE
EtOAc 1 1 [67] [68] NLP
iPrOAc 1 1 [67] [68] NLP
iBuOAc 1 1 [67] [68] NLP
Atropine Nerve agents LLE
EtOAc 2 4 [69] [70] MINLP
BuOAc 2 4 [69] [70] MINLP




SR = 00% 3 3 [71] [72] NLP
SR = 40% 3 3 [71] [72] NLP
SR = 80% 3 3 [71] [72] NLP
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3.2. Plant Design Performance Metrics
Process performance metrics encompassing technical performance, process intensity and costs are
compared for different APIs and selected separation option. The process metrics considered for the
comparative evaluation presented here are: Plantwide API recovery; Mass Productivity, MP = Mass of
Product / Total Mass in Process (a measure of how efficiently material is used in a process [73]); Number
of reaction and separation stages—a measure of process intensity; Capital (CapEx) and Operating
(OpEx) Expenditures per unit mass of API produced.
The process metrics for each API case and design option are listed in Table 2 and illustrated
for comparative evaluation via a radar plot in Figure 17. Each axis (process performance metric) in
Figure 17 bears a different meaning depending on whether it has a high or low value. Clearly, high
plantwide recoveries and MP but lower cost components are desirable. For the number of reaction and
separation stages, reverse-ordered axes are used to illustrate that lower values are preferable (i.e., fewer
unit operations equate to lower process complexity). The greater total surface area that a design option
covers in Figure 17, the better the process design is; it is also important that a design is sufficiently
high in all categories, not just highly performing in a few. For each API, the number of reactions and
separation stages have the same coordinates for each different separation option.










PhMe 89.2 44.7 195.9 15.3 211.2 [63]
nHex 89.5 43.2 192.7 15.2 207.9 [63]
Artemisinin Crystallization
EtOH 36.1 35.1 389.6 1.5 391.2 [63]
EtOAc 57.7 28.1 414.9 1.7 416.6 [63]
Diphenhydramine LLE
CyHex 88.3 27.1 89.6 64.5 154.1 [66]
MeCyHex 81.1 31.1 92.8 22.7 115.5 [66]
nHep 53.1 48.2 118.4 36.3 154.7 [66]
Warfarin LLE
EtOAc 85.7 57.1 71.5 78.5 150.0 [68]
iPrOAc 78.8 62.2 68.4 85.4 153.8 [68]
iBuOAc 84.8 58.4 66.7 80.2 146.9 [68]
Atropine LLE
Et2O 79.3 50.4 90.1 122.6 212.7 [70]
BuOAc 77.8 68.0 91.8 126.7 218.5 [70]
PhMe 81.0 62.9 88.5 108.7 197.2 [70]
Nevirapine Crystallization
SR = 0% 86.7 144.5 14.3 223.6 237.8 [72]
SR = 40% 86.4 89.0 14.2 147.3 161.5 [72]
SR = 80% 85.0 30.5 13.8 64.5 78.3 [72]
For ibuprofen, the different separation options (LLE solvent = {PhMe, nHex}) give similar
results and thus the LLE solvent with the lower environmental/EHS impact (PhMe) is preferred [74].
For warfarin, each LLE solvent performs comparably, but has similar EHS characteristics; solvent
selection should thus be informed by subsequent crystallization process design and the possibility for
solvent harmonization, recovery and recycling.
For artemisinin, plantwide performance varies more significantly with antisolvent choice.
The greater difference can be attributed to the different thermodynamic behaviors of the two antisolvents
with the inlet mixture (toluene) due to the different polarities and functional groups on each antisolvent.
For artemisinin, EtOH as antisolvent allows for lower costs and is more environmentally friendly than
EtOAc; thus EtOH is the better antisolvent choice.
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Figure 17. Performance metrics of various CPM processes for different APIs. 
For warfarin, the performances between different LLE solvent choices is comparable due to the 
similar thermodynamic behaviors of the ternary systems. For atropine, the LLE solvent choices 
perform comparably despite their different molecular structures, but Et2O and PhMe are less 
favorable than BuOAc with respect to their EHS characteristics; as for warfarin, consultation with 
processing requirements downstream and for plantwide operation + material efficiency is required. 
For nevirapine CPM, various values of Solvent Recovery (SR) are considered; whilst high SR (=80%) 
is attainable in laboratory-scale conditions, lower values are likely to be possible at larger scale 
operation. The assumed SR drastically affects OpEx, which is a significant contribution towards total 
costs, i.e., OpEx >> CapEx. 
Pharmaceutical manufacturing is typically quite intensive in terms of material and energy 
consumption due to the multistep synthetic routes required to synthesize APIs as well as strict quality 


































































Figure 17. Performance metrics of various CPM processes for different APIs.
Similarly for diphenhydramine, the different separation performances between the different
LLE solvent choices is due to the different thermodynamic behavior of the ternary system and hence
phase splitting and API partitioning between the resulting organic (product) and aqueous (waste)
phases; this is also due to the differences between the molecular structure of the LLE solvent choices.
For diphenhydramine, nHep has both poorer EHS characteristics than either CyHex or MeCyHex as
well as incurring higher costs; thus, either of the cycloalkane solvent choices is preferable.
For warfarin, the performances between different LLE solvent choices is comparable due to
the similar thermodynamic behaviors of the ternary systems. For atropine, the LLE solvent choices
perform comparably despite their different molecular structures, but Et2O and PhMe are less favorable
than BuOAc with respect to their EHS characteristics; as for warfarin, consultation with processing
requirements downstream and for plantwide operation + aterial efficiency is required. For nevirapine
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CPM, various values of Solvent Recovery (SR) are considered; whilst high SR (=80%) is attainable in
laboratory-scale conditions, lower values are likely to be possible at larger scale operation. The assumed
SR drastically affects OpEx, which is a significant contribution towards total costs, i.e., OpEx >> CapEx.
Pharmaceutical manufacturing is typically quite intensive in terms of material and energy
consumption due to the multistep synthetic routes required to synthesize APIs as well as strict quality
requirements which must be met prior to human consumption. Molecular Complexity Indices (CIs) are
often used to quantify the complexity/difficulty to synthesize a molecule with respect to its structure.
The most popular metric is the Bertz CI, which varies with the different numbers and types of functional
groups and their interconnections [75,76].
Our previous work has established correlations between complexity and economic parameters
for a large set of top selling antibiotics [77,78]. Here, we examine the different performance metrics
considered in Section 3.2 vs. their respective Molecular Weights (MWs) and CIs. Figure 18 shows
plantwide recovery, E-factor and total costs vs. MW and CI for different API cases. For the dataset
considered here, there is no obvious correlation between the performance metrics and MW/CI. Despite
this, there are some observations to be made. The lowest plantwide recovery (by API) is artemisinin,
which also has the highest costs. Designs for the considered APIs in this study have typical plantwide
recoveries = 70–90% (with some outliers) and varying E-factors (E = 20–80), which are all either good
or reasonable for pharmaceutical manufacturing [79–81]. This highlights that beyond this API recovery
that cost benefits are incremental at best. Nevirapine has significantly higher E-factors than other APIs
due to the purification implemented prior to crystallization via pH change, as described in the original
literature studies [71,72].
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These results illustrate that some of these CPM processes are leaner/further developed than
others, i. ., t r re still process improvements to be made with respect to cost reductions and plant
efficiencies. ld be noted that diff rent meth dologies hav been applie for different API cases
(se Table 1) paring the design solutions pres nted here for different APIs and separation
options; rt ele s, the results pr sented in this study illustrate different attainable regions of
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plantwide performance typical of CPM for the considered APIs, which have been highlighted as
amenable to CPM success in both their flow synthesis and modeling demonstrations.
Figure 19 compares the attained E-factors (a measure of material efficiency) vs. plantwide
recoveries. For ibuprofen, the attained recoveries, and thus E-factors, are similar for both LLE
solvent choices (nHex, PhMe). For artemisinin, diphenhydramine and warfarin, the E-factor decreases
(i.e., material efficiency improves) as plantwide recovery increases—this is expected, as waste quantities
are lower when the plant API recovery is high for a specified plant API capacity. For atropine, the same
trend is not observed; this is due to different quantities of separation solvent being used between design
cases in order to attain total cost minima in the design cases [70]. For nevirapine, the different design
cases correspond to different solvent recovery assumptions; evidently, as SR increases, the E-factor
improves (i.e., decreases).
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Figure 19. Plantwide E-factors vs. attained API recoveries for different design cases.
3.3. API Cost Component Contributions
Figure 17 shows overall API cost contributions comparatively. Figure 20 shows the cost comp nent
contributions on a more detailed level to gain deeper insight into API cost contributions and how
these are related to the design options selected from our previous studies. CapEx contributions are the
Battery Limits Installed Cost (BLIC) and Working Capital and Contingency (WCC); OpEx contributions
are materials and Utilities + Waste (U&W) [63].
For ibuprofen, total cost components are dominated by CapEx, which is in turn predominantly
BLIC components for both LLE solvents. Similar results are also observed for artemisinin, which
implements antisolvent crystallization. For artemisinin, OpEx contributions are so low due to the main
feedstock, DHAA, being a waste product from an existing process and considered to have negligible
costs in its acquirement in comparison to the other material prices [63,64].
For diphenhydramine, OpEx contributions are more significant than for ibuprofen and artemisinin.
Greater LLE solvent usage was used for the diphenhydramine design cases (in terms of the mass
ratio of separation solvent-to-incoming feed stream) than for ibuprofen and artemisinin. The OpEx
contributions for MeCyHex are lower than for CyHex due to its lower material price and similar
recovery (and th s flowrates and equipme t sizes) [66]. The CapEx contributions for this API are
less impactful due to l ss equipm nt bei g used, i.e., only one synthesis and one separation stage for
diphenhydramine [65]. Pr cess intensific tion and simplification is an excellent way to reduce costs and
strea line production. Simila trends are observed for both warfarin and atropine, with components
being similar across different separation options due to their similar performances (i.e., recoveries).
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are considered in different studies. Each case study considered upstream plant total costs as the
economic metric for comparative evaluation of different process designs. Comparison of optimal Net
Present Values (NPVs) can also provide valuable insight and alternative process designs for different
APIs, but are subject to API sales price variation, which may be quite significant for certain drugs
(e.g., artemisinin). Ultimately, when choosing whether to switch to continuous operation, clear operational
and economic benefits must be clear over traditional/current manufacturing methods for the API.
4. Conclusions
Design space investigation of CPM is a useful task in elucidating the attainable regions of operation
and process efficiency and attainable product quality. The literature contains many demonstrations that
have elucidated operating regions and mapped design spaces on a technical basis at unit operation level
for API synthesis, purification and downstream formulation, but not integrated stages thereof. In this
study, we compare technoeconomic plantwide analyses for upstream CPM (reaction + separation) for
various APIs considered by our group, all of which have high economic impact and societal importance.
The design space investigation for each API considers reaction + purification/separation, with the
main tuning parameters between design cases pertaining to the separation processes, which have
receive little attention in comparison to the number of literature studies on synthesis optimization.
Comparative evaluation of different design cases is on the basis of technical, operational, economic and
EHS criteria. Currently, decisions on whether to operate continuously is made on a case-by-case/API
basis. Elucidating operating regions for demonstrated CPM for different APIs is an important step
towards more systematic selection and screening of promising candidates for continuous production.
Author Contributions: Conceptualization, S.D. and D.I.G.; Methodology, S.D. and D.I.G.; Software, S.D.;
Validation, S.D.; Formal Analysis, S.D. and D.I.G.; Writing, S.D. and D.I.G., Supervision: D.I.G. All authors have
read and agreed to the published version of the manuscript.
Funding: S.D. and D.I.G. both acknowledge the support of the Great Britain Sasakawa and Nagai Foundations.
S.D. acknowledges the Engineering and Physical Sciences Research Council (EPSRC) via a Doctoral Training
Partnership PhD Fellowship (Grant #EP/N509644/1). D.I.G. acknowledges a Royal Academy of Engineering
(RAEng) Industrial Fellowship.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the study. Tabulated
and cited literature data suffice for the reproduction of all original results and no other supporting data are
required to ensure reproducibility.
References
1. Poechlauer, P.; Colberg, J.; Fisher, E.; Jansen, M.; Johnson, M.D.; Koenig, S.G.; Lawler, M.; Laporte, T.;
Manley, J.; Martin, B.; et al. Pharmaceutical roundtable study demonstrates the value of continuous
manufacturing in the design of greener processes. Org. Process Res. Dev. 2013, 17, 1472–1478. [CrossRef]
2. Teoh, S.K.; Rathi, C.; Sharratt, P. Practical assessment methodology for converting fine chemicals processes
from batch to continuous. Org. Process Res. Dev. 2015, 20, 414–431. [CrossRef]
3. Bana, P.; Örkényi, R.; Lövei, K.; Lakó, Á.; Túrós, G.I.; Éles, J.; Faigl, F.; Greiner, I. The route from problem to
solution in multistep continuous flow synthesis of pharmaceutical compounds. Bioorg. Med. Chem. 2017, 25,
6180–6189. [CrossRef] [PubMed]
4. Costandy, J.G.; Edgar, T.F.; Baldea, M. Switching from batch to continuous reactors is a trajectory optimization
problem. Ind. Eng. Chem. Res. 2019, 58, 13718–13736. [CrossRef]
5. Plumb, K. Continuous processing in the pharmaceutical industry—Changing the mind set. Chem. Eng. Res.
Des. 2005, 83, 730–738. [CrossRef]
6. McWilliams, J.C.; Allian, A.D.; Opalka, S.M.; May, S.A.; Journet, M.; Braden, T.M. The evolving state of
continuous processing in pharmaceutical API manufacturing: A survey of pharmaceutical companies and
contract manufacturing organizations. Org. Process Res. Dev. 2018, 22, 1143–1166. [CrossRef]
7. Baumann, M.; Baxendale, I.R. The synthesis of active pharmaceutical ingredients (APIs) using continuous
flow chemistry. Beilstein J. Org. Chem. 2015, 11, 1194–1219. [CrossRef]
Pharmaceutics 2020, 12, 235 21 of 24
8. Plutschack, M.B.; Pieber, B.; Gilmore, K.; Seeberger, P.H. The Hitchhiker’s guide to flow chemistry. Chem. Rev.
2017, 117, 11796–11893. [CrossRef]
9. Britton, J.; Raston, C.L. Multi-step continuous-flow synthesis. Chem. Soc. Rev. 2017, 52, 10159–10162. [CrossRef]
10. De Souza, R.O.M.A.; Watts, P. Flow processing as a tool for API production in developing economies. J. Flow
Chem. 2017, 7, 146–150. [CrossRef]
11. Malet-Sanz, L.; Susanne, F. Continuous flow synthesis. A pharma perspective. J. Med. Chem. 2012, 55,
4062–4098. [CrossRef] [PubMed]
12. Rossetti, I.; Compagnoni, M. Chemical reaction engineering, process design and scale-up issues at the frontier
of synthesis: Flow chemistry. Chem. Eng. J. 2016, 296, 56–70. [CrossRef]
13. Adamo, A.; Beingessner, R.L.; Behnam, M.; Chen, J.; Jamison, T.F.; Jensen, K.F.; Monbaliu, J.-C.M.;
Myerson, A.S.; Revalor, E.M.; Snead, D.R.; et al. On-demand continuous-flow production of pharmaceuticals
in a compact, reconfigurable system. Science 2016, 352, 61–67. [CrossRef] [PubMed]
14. Cole, K.P.; Reizman, B.J.; Hess, M.; Groh, J.M.; Laurila, M.E.; Cope, R.F.; Campbell, B.M.; Forst, M.B.; Burt, J.L.;
Maloney, T.D.; et al. Small-volume continuous manufacturing of merestinib. Part 1. Process development
and demonstration. Org. Process Res. Dev. 2019, 23, 858–869. [CrossRef]
15. Reizman, B.J.; Cole, K.P.; Hess, M.; Burt, J.L.; Maloney, T.D.; Johnson, M.D.; Laurila, M.E.; Cope, R.F.;
Luciani, C.V.; Buser, J.Y.; et al. Small-volume continuous manufacturing of merestinib. Part 2. Technology
transfer and cgmp manufacturing. Org. Process Res. Dev. 2019, 23, 870–881. [CrossRef]
16. Baxendale, I.R.; Braatz, R.D.; Hodnett, B.K.; Jensen, K.F.; Johnson, M.D.; Sharratt, P.; Sherlock, J.P.; Florence, A.J.
Achieving continuous manufacturing: Technologies and approaches for synthesis, workup, and isolation of
drug substance. May 20–21 2014 Continuous manufacturing symposium. J. Pharm. Sci. 2015, 104, 781–791.
[CrossRef]
17. Lee, J.W.; Horváth, Z.; O’Brien, A.G.; Seeberger, P.H.; Seidel-Morgenstern, A. Design and optimization of
coupling a continuously operated reactor with simulated moving bed chromatography. Chem. Eng. J. 2014,
251, 355–370. [CrossRef]
18. Wang, J.; Lakerveld, R. Continuous membrane-assisted crystallization to increase the attainable product quality
of pharmaceuticals and design space for operation. Ind. Eng. Chem. Res. 2017, 56, 5705–5714. [CrossRef]
19. Drageset, A.; Bjørsvik, H.-R. Continuous flow synthesis concatenated with continuous flow liquid–liquid
extraction for work-up and purification: Selective mono- and di-iodination of the imidazole backbone.
React. Chem. Eng. 2016, 1, 436–444. [CrossRef]
20. Monbaliu, J.-C.M.; Stelzer, T.; Revalor, E.; Weeranoppanant, N.; Jensen, K.F.; Myerson, A.S. Compact and
integrated approach for advanced end-to-end production, purification, and aqueous formulation of lidocaine
hydrochloride. Org. Process Res. Dev. 2016, 20, 1347–1353. [CrossRef]
21. Weeranoppanant, N.; Adamo, A.; Saparbaiuly, G.; Rose, E.; Fleury, C.; Schenkel, B.; Jensen, K.F. Design of
multistage counter-current liquid–liquid extraction for small-scale applications. Ind. Eng. Chem. Res. 2017,
56, 4095–4103. [CrossRef]
22. Zhang, D.; Xu, S.; Du, S.; Wang, J.; Gong, J. Progress of pharmaceutical continuous crystallization. Engineering
2017, 3, 354–364. [CrossRef]
23. Chen, J.; Sarma, B.; Evans, J.M.B.; Myerson, A.S. Pharmaceutical crystallization. Cryst. Growth Des. 2011, 11,
887–895. [CrossRef]
24. Randolph, A.D.; Larson, M.A. Theory of Particulate Processes: Analysis and Techniques of Continuous Crystallization;
Academic Press: Cambridge, UK, 1988.
25. Eder, R.J.P.; Schmitt, E.K.; Grill, J.; Radl, S.; Gruber-Woelfler, H.; Khinast, J.G. Seed loading effects on the
mean crystal size of acetylsalicylic acid in a continuous-flow crystallization device. Cryst. Res. Technol. 2011,
46, 227–237. [CrossRef]
26. McGlone, T.; Briggs, N.E.B.; Clark, C.A.; Brown, C.J.; Sefcik, J.; Florence, A.J. Oscillatory flow reactors (OFRs)
for continuous manufacturing and crystallization. Org. Process Res. Dev. 2015, 19, 1186–1202. [CrossRef]
27. Alvarez, A.J.; Myerson, A.S. Continuous plug flow crystallization of pharmaceutical compounds.
Cryst. Growth Des. 2010, 10, 2219–2228. [CrossRef]
28. Lawton, S.; Steele, G.; Shering, P.; Zhao, L.; Laird, I.; Ni, X.-W. Continuous crystallization of pharmaceuticals
using a continuous oscillatory baffled crystallizer. Org. Process Res. Dev. 2009, 13, 1357–1363. [CrossRef]
Pharmaceutics 2020, 12, 235 22 of 24
29. Eder, R.J.P.; Radl, S.; Schmitt, E.; Innerhofer, S.; Maier, M.; Gruber-Woelfler, H.; Khinast, J.G. Continuously
seeded, continuously operated tubular crystallizer for the production of active pharmaceutical ingredients.
Cryst. Growth Des. 2010, 10, 2247–2257. [CrossRef]
30. Su, Q.; Benyahia, B.; Nagy, Z.K.; Rielly, C.D. Mathematical modeling, design, and optimization of a
multisegment multiaddition plug-flow crystallizer for antisolvent crystallizations. Org. Process Res. Dev.
2015, 19, 1859–1870. [CrossRef]
31. Vetter, T.; Burcham, C.L.; Doherty, M.F. Regions of attainable particle sizes in continuous and batch
crystallization processes. Chem. Eng. Sci. 2014, 106, 167–180. [CrossRef]
32. Ridder, B.J.; Majumder, A.; Nagy, Z.K. Parametric, optimization-based study on the feasibility of a
multisegment antisolvent crystallizer for in situ fines removal and matching of target size distribution.
Ind. Eng. Chem. Res. 2016, 55, 2371–2380. [CrossRef]
33. Su, Q.; Ganesh, S.; Moreno, M.; Bommireddy, Y.; Gonzalez, M.; Reklaitis, G.V.; Nagy, Z.K. A perspective
on quality-by-control (QbC) in pharmaceutical continuous manufacturing. Comput. Chem. Eng. 2019, 125,
216–231. [CrossRef]
34. Martinetz, M.C.; Rehrl, J.; Aigner, I.; Sacher, S.; Khinast, J. A continuous operation concept for a rotary tablet
press using mass flow operating points. Chem. Ing. Tech. 2017, 89, 1006–1016. [CrossRef]
35. Metta, N.; Ghijs, M.; Schäfer, E.; Kumar, A.; Cappuyns, P.; Assche, I.; Singh, R.; Ramachandran, R.; de Beer, T.;
Ierapetritou, M.; et al. Dynamic flowsheet model development and sensitivity analysis of a continuous
pharmaceutical tablet manufacturing process using the wet granulation route. Processes 2019, 7, 234. [CrossRef]
36. Hsu, S.H.; Reklaitis, G.V.; Venkatasubramanian, V. Modeling and control of roller compaction for
pharmaceutical manufacturing. Part I: Process dynamics and control framework. J. Pharm. Innov. 2010, 5,
14–23. [CrossRef]
37. Hsu, S.H.; Reklaitis, G.V.; Venkatasubramania, V. Modeling and control of roller compaction for
pharmaceutical manufacturing: Part II: Control system design. J. Pharm. Innov. 2010, 5, 24–36. [CrossRef]
38. Bano, G.; Facco, P.; Ierapetritou, M.; Bezzo, F.; Barolo, M. Design space maintenance by online model
adaptation in pharmaceutical manufacturing. Comput. Chem. Eng. 2019, 127, 254–271. [CrossRef]
39. Tian, G.; Koolivand, A.; Arden, N.S.; Lee, S.; O’Connor, T.F. Quality risk assessment and mitigation of
pharmaceutical continuous manufacturing using flowsheet modeling approach. Comput. Chem. Eng. 2019,
129, 106508. [CrossRef]
40. Lee, S.L.; O’Connor, T.F.; Yang, X.; Cruz, C.N.; Chatterjee, S.; Madurawe, R.D.; Moore, C.M.V.; Yu, L.X.;
Woodcock, J. Modernizing pharmaceutical manufacturing: From batch to continuous production. J. Pharm.
Innov. 2015, 10, 191–199. [CrossRef]
41. Mascia, S.; Heider, P.L.; Zhang, H.; Lakerveld, R.; Benyahia, B.; Barton, P.I.; Braatz, R.D.; Cooney, C.L.;
Evans, J.M.B.; Jamison, T.F.; et al. End-to-end continuous manufacturing of pharmaceuticals: Integrated
synthesis, purification, and final dosage formation. Angew. Chem. Int. Ed. 2013, 52, 12359–12363. [CrossRef]
42. CPI Works with GSK and AstraZeneca on Pharma Manufacturing. Available online: https://www.uk-cpi.
com/news/delivering-effective-continuous-wet-granulation-processes (accessed on 20 February 2020).
43. How GSK Launched a Continuous Manufacturing Pilot Plant—And What it Learned. Available
online: https://www.pharmaceuticalonline.com/doc/how-gsk-launched-a-continuous-manufacturing-pilot-
plant-and-what-it-learned-0001 (accessed on 20 February 2020).
44. Drug Companies Warm Up to Continuous Manufacturing—American Chemical Society. Available
online: https://www.acs.org/content/acs/en/pressroom/presspacs/2019/acs-presspac-may-1-2019/drug-
companies-warm-up-to-continuous-manufacturing.html (accessed on 20 February 2020).
45. Quality by Design (QbD) for the Continuous Manufacturing of Solid Oral Dosage Forms. Available online:
http://pqri.org/wp-content/uploads/2015/11/Embiata-Smith.pdf (accessed on 20 February 2020).
46. GSK Invests a Further $77mil to Enhance Antibiotic Manufacturing Facility in Singapore. Available
online: http://sg.gsk.com/en-sg/media/press-releases/2015/gsk-invests-a-further-s-77mil-to-enhance-antibiotic-
manufacturing-facility-in-singapore/ (accessed on 3 February 2016).
47. Palmer, E. GSK Opens $95M Continuous Production Operation in Singapore. Available online: https://www.
fiercepharma.com/manufacturing/gsk-opens-130m-continuous-production-facilities-singapore (accessed on
21 February 2020).
Pharmaceutics 2020, 12, 235 23 of 24
48. Bailey, C.K.; Caltabiano, S.; Cobitz, A.R.; Huang, C.; Mahar, K.M.; Patel, V.V. A randomized, 29-day,
dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with
anemia on hemodialysis. BMC Nephrol. 2019, 20, 372. [CrossRef] [PubMed]
49. FDA Approves Tablet Production on Janssen Continuous Manufacturing Line. Available online: http:
//www.pharmtech.com/fda-approves-tablet-production-janssen-continuous-manufacturing-line (accessed
on 7 October 2016).
50. Meet Eli Lilly and Company—2019 Facility of the Year Process Innovation Category Winner | Pharmaceutical
Engineering. Available online: https://ispe.org/pharmaceutical-engineering/ispeak/meet-eli-lilly-and-
company-2019-facility-year-process-innovation (accessed on 21 February 2020).
51. Bédard, A.-C.; Adamo, A.; Aroh, K.C.; Russell, M.G.; Bedermann, A.A.; Torosian, J.; Yue, B.; Jensen, K.F.;
Jamison, T.F. Reconfigurable system for automated optimization of diverse chemical reactions. Science 2018,
361, 1220–1225. [CrossRef] [PubMed]
52. Armstrong, C.T.; Pritchard, C.Q.; Cook, D.W.; Ibrahim, M.; Desai, B.K.; Whitham, P.J.; Marquardt, B.J.;
Chen, Y.; Zoueu, J.T.; Bortner, M.J.; et al. Continuous flow synthesis of a pharmaceutical intermediate:
A computational fluid dynamics approach. React. Chem. Eng. 2019, 4, 634–642. [CrossRef]
53. Reizman, B.J.; Jensen, K.F. Simultaneous solvent screening and reaction optimization in microliter slugs.
Chem. Commun. 2015, 51, 13290–13293. [CrossRef]
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